Clonal Hematopoiesis and Premalignant Diseases

Justin D. Kaner(NewYork–Presbyterian Hospital), Duane C. Hassane(AstraZeneca (Singapore)), Gail J. Roboz(Cornell University), Nuria Mencia-Trinchant(NewYork–Presbyterian Hospital), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Pinkal Desai(NewYork–Presbyterian Hospital)
Cold Spring Harbor Perspectives in Medicine
October 15, 2019
10.1101/cshperspect.a035675
Cited by 20

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714